Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness.

Journal of Acquired Immune Deficiency Syndromes : JAIDS
Zixin Hu, Daniel R Kuritzkes

Abstract

Raltegravir resistance is conferred by mutations at integrase codons 143, 148, and 155 together with associated secondary mutations. The N155H mutants emerge first, and are eventually replaced by Q148H mutants, usually in combination with G140S. These mutations have different effects on susceptibility and replication capacity, but data on the relative fitness of RAL-resistant viruses are limited. To understand the impact of the different RAL resistance pathways on viral fitness, mutations at integrase codons 74, 92, 138, 140, 148, 155, and/or 163 were introduced into HIV-1NL4-3 by site-directed mutagenesis and expressed in recombinant viruses. Relative fitness and drug susceptibility were determined in the absence or presence of RAL. In the absence of drug, RAL-resistant mutants were less fit than wild type, and the Q148H mutant was significantly less fit than the N155H mutant. Fitness was partially restored by the presence of additional RAL resistance mutations at positions G140S and E92Q or E138K, respectively. In the presence of RAL, the N155H mutant remained fitter than the Q148H mutant, but the G140S/Q148H double mutant was fitter than single mutants or the E92Q/N155H double mutant. These findings correspond well with the ...Continue Reading

References

Feb 26, 1998·Antiviral Research·E Asante-Appiah, A M Skalka
Jun 29, 1999·Advances in Virus Research·D Esposito, R Craigie
Nov 11, 1999·Proceedings of the National Academy of Sciences of the United States of America·Y GoldgurD R Davies
Dec 10, 1999·Microbiology and Molecular Biology Reviews : MMBR·P Hindmarsh, J Leis
Jun 19, 2001·Journal of Acquired Immune Deficiency Syndromes : JAIDS·J Lu, D R Kuritzkes
Feb 3, 2007·Current Pharmaceutical Design·Jinxia DengNouri Neamati
Dec 22, 2007·Expert Opinion on Investigational Drugs·Mary Anker, Roberto B Corales
Jan 30, 2008·Antimicrobial Agents and Chemotherapy·Isabelle MaletAnne-Geneviève Marcelin
Jul 23, 2008·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Vincent MarconiDaniel R Kuritzkes
Nov 11, 2009·Antimicrobial Agents and Chemotherapy·Olivier DelelisJean-François Mouscadet

❮ Previous
Next ❯

Citations

Apr 9, 2011·Medical Microbiology and Immunology·Saleta SierraUNKNOWN SnoB-Study group
Nov 28, 2012·Current Infectious Disease Reports·Peter K QuashieMark A Wainberg
Apr 5, 2011·The Journal of Infectious Diseases·Jose-Luis BlancoRobert W Shafer
Apr 13, 2012·Journal of Virology·Mark A BrockmanZabrina L Brumme
Dec 25, 2012·BMC Infectious Diseases·Miłosz ParczewskiAnna Boroń-Kaczmarska
Dec 14, 2011·Journal of Translational Medicine·Beatriz MotheChristian Brander
Apr 14, 2012·BMC Medicine·Peter K QuashieMark A Wainberg
Feb 16, 2013·HIV/AIDS : Research and Palliative Care·Alessandra FantauzziIvano Mezzaroma
Jun 23, 2011·Infection and Drug Resistance·Jean L MbisaPatricia A Cane
Oct 14, 2011·Viruses·Karoll J Cortez, Frank Maldarelli
Oct 23, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Christopher B HurtJoseph J Eron
Aug 22, 2015·Expert Review of Anti-infective Therapy·Tae Eun ParkRoopali Sharma
Dec 14, 2011·Current Opinion in Virology·Daniel R Kuritzkes
Sep 26, 2015·The Journal of Antimicrobial Chemotherapy·Chung-Chih LaiChien-Ching Hung
Sep 19, 2012·Current Opinion in Virology·Andrew R Wargo, Gael Kurath
Jul 31, 2013·Journal of Structural Biology·Tamaria G DewdneyLadislau C Kovari
Sep 30, 2016·Retrovirology·Janani VaradarajanStephen H Hughes
Jul 13, 2018·Journal of Virology·Doty B A OjwachJaclyn K Mann
Oct 15, 2011·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Rima KulkarniKirsten L White
Jun 7, 2017·Retrovirology·Kaitlin AnstettMark A Wainberg
Jan 10, 2018·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Sanjay N PujariVivek Bele
Nov 22, 2011·Expert Review of Pharmacoeconomics & Outcomes Research·Mohammad Ashraf ChaudharyEsther C Nathanson
Oct 9, 2019·ELife·Avik BiswasRonald M Levy
May 22, 2020·Antiviral Chemistry & Chemotherapy·Wassim ChehadehShaikhah Al-Shammari
Dec 15, 2020·Virology·Doty B A OjwachJaclyn K Mann
Mar 19, 2021·International Immunopharmacology·Namrata M Nilavar, Sathees C Raghavan
Mar 9, 2021·AIDS Research and Human Retroviruses·Alexander J BaileyRobert W Shafer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.